GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic beta;-cells from glucolipotoxicity

Journal of Endocrinology

Volumn 213, Issue 2, 2012, Pages 143-154

  Liu, Zhengu ^a,b   Stanojevic, Violeta ^a   Brindamour, Luke J ^a   Habener, Joel F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b A Novartis Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [28-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; TERT BUTYL HYDROPEROXIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL LABELING; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; LIPOTOXICITY; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; HYDROGEN PEROXIDE; INSULIN; INSULIN-SECRETING CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OLEIC ACID; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTORS, GLUCAGON; TERT-BUTYLHYDROPEROXIDE; VENOMS;

EID: 84862058779     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0328     Document Type: Article

References (29)

1. Beinborn M, Worrall CI, McBride EW& Kopin AS 2005 A human glucagonlike peptide-1 receptor polymorphismresults in reduced agonist responsiveness. Regulatory Peptides 130 1-6.
2. Brandsch M, Knütter I & Bosse-Doenecke E 2008 Pharmaceutical and pharmacological importance of peptide transporters. Journal of Pharmacy and Pharmacology 60 543-585.
3. Butler PC, Meier JJ, Butler AE & Bhushan A 2007 The replication of b cells in normal physiology, in disease and for therapy. Nature Clinical Practice. Endocrinology & Metabolism 3 758-768.
4. Demers A, Rodrigue-Way A & Tremblay A 2008 Hexarelin signaling to PPARgamma in metabolic diseases. PPAR Research 2008 364784.
5. Ganapathy V &Miyauchi S 2005 Transport systems for opioid peptides in mammalian tissues. AAPS Journal 7 E852-E856.
6. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A & Palasciano G 2008 Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. Journal of Nutrition and Biochemistry 19 491-504.
7. Haas JT & Biddinger SB 2009 Dissecting the role of insulin resistance in the metabolic syndrome. Current Opinion in Lipidology 20 206-210.
8. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, Zimmermann B & Voigt K 1995 Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regulatory Peptides 58 149-156. (doi:10. 1016/0167-0115(95)00063-H)
9. Hupe-Sodmann K, Göke R, Göke B, Thole HH, Zimmermann B, Voigt K & McGregor GP 1997 Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides 18 625-632.
10. Leahy JL 2005 Pathogenesis of type 2 diabetes mellitus. Archives of Medical Research 36 197-209.
11. Liu Z & Habener JF 2008 Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic b cell proliferation. Journal of Biological Chemistry 283 8723-8735.
12. Liu Z & Habener JF 2009 Stromal cell-derived factor-1 promotes survival of pancreatic b cells by the stabilisation of b-catenin and activation of transcription factor 7-like 2 (TCF7L2). Diabetologia 52 1589-1598.
13. Liu Z, Stanojevic V, Avadhani S, Yano T & Habener JF 2011 Stromal cellderived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances b cell survival. Diabetologia 54 2067-2076.
14. Lovshin JA&DruckerDJ 2009 Incretin-based therapies for type 2 diabetesmellitus. Nature Reviews. Endocrinology 5 262-269.
15. Maiese K, Morhan SD & Chong ZZ 2007 Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Current Neurovascular Research 4 63-71.
16. Moran A, Zhang HJ, Olson LK, Harmon JS, Poitout V & Robertson RP 1997 Differentiation of glucose toxicity from b cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. Journal of Clinical Investigation 99 534-539.
17. Nyalakonda K, Sharma T & Ismail-Beigi F 2010 Preservation of b cell function in type 2 diabetes. Endocrine Practice 21 1-33. Oude Elferink RP & Zadina J 2001 MDR1 P-glycoprotein transports endogenous opioid peptides. Peptides 22 2015-2020.
18. Piret JP, Arnould T, Fuks B, Chatelain P, Remacle J & Michiels C 2004 Mitochondria permeability transition-dependent tert-butyl hydroperoxide-induced apoptosis in hepatoma HepG2 cells. Biochemical Pharmacology 67 611-620.
19. Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Santini SA, Zuppi C & Ghirlanda G 2010 Oxidative stress, nitric oxide, and diabetes. Review of Diabetic Studies 7 15-22.
20. Plamboeck A, Holst JJ, Carr RD & Deacon CF 2005 Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48 1882-1890.
21. Poitout V & Robertson RP 2008 Glucolipotoxicity: fuel excess and b-cell dysfunction. Endocrine Reviews 29 351-366.
22. Szeto HH 2006 Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS Journal 8 E277-E283.
23. Szoke E & Gerich JE 2005 Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Comprehensive Therapy 31 106-112.
24. Tomas E & Habener JF 2010 Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends in Endocrinology and Metabolism 21 59-67.
25. Tomas E, Stanojevic V & Habener JF 2010 GLP-1(9-36)amide metabolite suppression of glucose production in isolated mouse hepatocytes. Hormone and Metabolic Research 42 657-662.
26. Tomas E, Stanojevic V & Habener JF 2011a GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regulatory Peptides 167 177-184.
27. Tomas E, Wood JA, Stanojevic V & Habener JF 2011b GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Regulatory Peptides 169 43-48.
28. Whalley NM, Pritchard LE, Smith DM & White A 2011 Processing of proglucagon to GLP-1 in pancreatic a cells: is this a paracrine mechanism enabling GLP-1 to act on b cells? Journal of Endocrinology 211 99-106.
29. Zraika S, Hull RL, Udayasankar J, Clark A, Utzschneider KM, Tong J, Gerchman F & Kahn SE 2007 Identification of the amyloid-degrading enzyme neprilysin in mouse islets and potential role in islet amyloidogenesis. Diabetes 56 304-310.